{"title":"Start-Up Tolero Pharmaceuticals Licenses MannKind’s Btk Programme in US$130 M Deal","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I5.1740","DOIUrl":null,"url":null,"abstract":"In a deal worth approximately US$130 M, start-up Tolero Pharmaceuticals has licensed worldwide rights to develop and commercialise compounds from MannKind’s Btk (Bruton’s tyrosine kinase) programme, which are being developed for the treatment of haematological malignancies and inflammatory diseases. Interestingly, MannKind retains the right to reacquire the Btk assets at prespecified terms up to 60 days after completion of the first Phase I study.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I5.1740","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In a deal worth approximately US$130 M, start-up Tolero Pharmaceuticals has licensed worldwide rights to develop and commercialise compounds from MannKind’s Btk (Bruton’s tyrosine kinase) programme, which are being developed for the treatment of haematological malignancies and inflammatory diseases. Interestingly, MannKind retains the right to reacquire the Btk assets at prespecified terms up to 60 days after completion of the first Phase I study.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
